A groundbreaking study has found that asthma medicine may cut the risk of developing Parkinson’s disease by nearly 50 percent. Researchers from the University of Bergen (UiB) and Harvard University analyzed data from one of the most comprehensive prescription registries in the world to reach this conclusion, and their findings are already reshaping how the scientific community thinks about Parkinson’s prevention and treatment.
Parkinson’s disease is a chronic neurological condition with no known cause. It progressively destroys the dopamine producing cells in the brain that regulate movement, balance, and coordination. Patients typically experience tremors, muscle stiffness in the arms and legs, slow movement, and difficulty with coordination. Over time, these symptoms interfere with everyday activities including speaking, writing, and walking. Because symptoms often develop gradually and resemble other conditions, it can take months or even years to receive an accurate diagnosis.
What Is Parkinson’s Disease and Why Does It Matter?
Parkinson’s disease affects more than 10 million people worldwide and is the second most common neurodegenerative disorder after Alzheimer’s. Despite decades of research, there is still no cure. Current treatments focus on managing symptoms rather than slowing or reversing the underlying disease process. That is what makes this study on asthma medicine and Parkinson’s risk so significant.
Understanding the biological mechanisms behind Parkinson’s is essential to finding new treatment pathways. Researchers have long focused on the role of a protein called alpha synuclein, which clumps together in the brains of Parkinson’s patients. These clusters are believed to damage or destroy the neurons responsible for producing dopamine, the chemical messenger that coordinates smooth, controlled movement.
The Study: 100 Million Prescriptions Analyzed
Researchers at the Department of Global Health and Social Medicine (IGS) at the University of Bergen, working alongside colleagues from Harvard University, conducted a large scale population study published in the journal Science. The research drew on data from Norway’s National Prescription Drug Registry, one of the most complete and detailed prescription databases in the world.
Professor Trond Riise at IGS, together with colleagues Anders Engeland and Kjetil Lauvland Bjørnevik, analyzed information from more than 100 million drug deliveries registered in the Prescription Registry since 2004. This allowed the team to examine patterns across the entire Norwegian population and identify meaningful connections between specific medications and the development of Parkinson’s disease.
“Our analyzes of data from the entire Norwegian population have been decisive for the conclusions of this study,” said Professor Riise.
The research focused specifically on two categories of medication: asthma medicine and blood pressure medicine. By cross referencing prescription data with Parkinson’s diagnoses, the team was able to determine that patients who used a particular class of asthma drugs were significantly less likely to develop Parkinson’s disease. The findings showed a risk reduction of approximately 50 percent in that group.
Why Asthma Medicine? The Science Behind the Connection
The investigation into asthma medicine and Parkinson’s risk began with laboratory work at Harvard University. Researchers there discovered that certain asthma and blood pressure medications had measurable effects on brain cells taken from Parkinson’s patients. In animal experiments, these drugs showed opposite effects: one category appeared to slow the accumulation of harmful alpha synuclein proteins, while the other appeared to accelerate it.
Motivated by those findings, the Harvard team reached out to UiB to test whether the same patterns would hold in human populations. Norway’s Prescription Registry provided the ideal dataset precisely because it captures the complete medication history of an entire country over many years.
The results mirrored what had been seen in the lab. Patients who had been prescribed the asthma medicine showed a significantly lower rate of Parkinson’s diagnosis compared to those who had not. Conversely, patients prescribed the other type of medication showed a higher rate.
“We analyzed the entire Norwegian population and found exactly the same effects as the animal experiments, and the pieces fell into place. These are medicines that have never been considered for Parkinson’s disease before,” said Professor Riise.
What This Means for Future Clinical Trials
The discovery that an existing, approved asthma medicine may reduce Parkinson’s risk by 50 percent opens a potentially fast track pathway for clinical trials. Because these medications are already approved for human use and have established safety profiles, researchers may be able to move into clinical testing more quickly than would be possible with a brand new compound.
“These findings provide a unique opportunity for new treatment of this serious disease, and we expect clinical trials to test the drug when these results become known,” said Professor Riise.
For the clinical research community, this represents exactly the kind of signal that drives Phase II and Phase III trial design. Repurposing an existing medicine for a new indication reduces development costs and timelines while leveraging decades of real world safety data.
FOMAT Medical Research has extensive experience supporting Phase I through Phase IV clinical trials across a range of therapeutic areas, including neurological and metabolic conditions. Our national network of community based investigators and centralized research teams is designed to accelerate enrollment and deliver high quality data for studies like these. If you are a Sponsor or CRO exploring neurology or related therapeutic areas, contact our team to learn how FOMAT can support your next study.
Key Takeaways
Asthma medicine may reduce the risk of Parkinson’s disease by approximately 50 percent based on population level data from over 100 million prescriptions. The study, published in Science, was conducted by UiB and Harvard University using Norway’s National Prescription Drug Registry. The findings are expected to lead to formal clinical trials testing the drug as a Parkinson’s prevention or treatment strategy. Repurposing an approved medication could significantly shorten the path from discovery to patient access.